in addition to improving lipid profiles and
reducing the rate of adverse cardiovascular outcomes
in patients with mixed dyslipidemia,may provide
renoprotection inpatients with type2 diabetes,
indicating that combination therapy may further
improve lipid profiles inpatients with CKD